- Home
- NVCR
NVCR
NovoCure Limited
as 07-26-2024 4:00pm EST
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
| Founded: | 2000 | Country: | Jersey |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 2.0B | IPO Year: | 2015 |
| Target Price: | $30.00 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.87 - $35.10 | Next Earning Date: | 07-25-2024 |
| Revenue: | $549,964,000 | Revenue Growth: | 8.33% |
| Revenue Growth (this year): | 10.97% | Revenue Growth (next year): | 7.67% |
Stock Insider Trading Activity of NovoCure Limited (NVCR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| VERNON W ANTHONY | NVCR | Director | Jun 4 '24 | Sell | $23.89 | 964 | $23,032.85 | 164,833 | SEC Form 4 |
| Scannell Timothy J | NVCR | Director | Jun 4 '24 | Sell | $23.89 | 964 | $23,027.45 | 2,964 | SEC Form 4 |
| LEUNG GABRIEL | NVCR | Director | Jun 4 '24 | Sell | $23.89 | 964 | $23,025.24 | 78,175 | SEC Form 4 |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Mar 1 '24 | Sell | $16.03 | 1,679 | $26,909.17 | 160,938 | SEC Form 4 |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Mar 1 '24 | Sell | $16.01 | 840 | $13,448.40 | 160,098 | SEC Form 4 |
| GROENHUYSEN WILHELMUS CM | NVCR | Chief Operating Officer | Mar 1 '24 | Sell | $16.03 | 2,107 | $33,768.68 | 252,452 | SEC Form 4 |
| GROENHUYSEN WILHELMUS CM | NVCR | Chief Operating Officer | Mar 1 '24 | Sell | $16.01 | 1,217 | $19,484.17 | 251,235 | SEC Form 4 |
| GROENHUYSEN WILHELMUS CM | NVCR | Chief Operating Officer | Feb 27 '24 | Sell | $16.14 | 2,303 | $37,176.87 | 254,559 | SEC Form 4 |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Feb 27 '24 | Sell | $16.14 | 2,078 | $33,544.74 | 162,617 | SEC Form 4 |
| Shah Pritesh | NVCR | Chief Growth Officer | Nov 7 '23 | Sell | $12.65 | 382 | $4,832.30 | 124,511 | SEC Form 4 |
Latest NovoCure Limited News
NVCR Breaking Stock News: Dive into NVCR Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
NovoCure (NVCR) Q2 2024 Earnings Call Transcript
MT Newswires
a day ago
NovoCure Q2 Loss Narrows, Net Revenue Increases
Zacks
2 days ago
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
Associated Press Finance
2 days ago
NovoCure: Q2 Earnings Snapshot
Business Wire
2 days ago
Novocure Reports Second Quarter 2024 Financial Results
Business Wire
a month ago
Novocure to Report Second Quarter 2024 Financial Results
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
Compare NVCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.